We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in CinCor Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 102 → 0 (-102)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $461M → $0 (-$461M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 102

Holders
–
Holders Change
-102
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
102
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
-$74.6M
2
5VM
5AM Venture Management
California
-$60.7M
3
GA
General Atlantic
New York
-$51.7M
4
PA
Perceptive Advisors
New York
-$31.7M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$24.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
– -$74.6M -6,073,949 Closed
5VM
2
5AM Venture Management
California
– -$60.7M -4,937,646 Closed
GA
3
General Atlantic
New York
– -$51.7M -4,209,470 Closed
PA
4
Perceptive Advisors
New York
– -$31.7M -2,576,325 Closed
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
– -$24.5M -1,994,583 Closed
O
6
OrbiMed
New York
– -$23.4M -1,906,000 Closed
BlackRock
7
BlackRock
New York
– -$21.9M -1,783,419 Closed
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
– -$17.5M -1,423,124 Closed
RI
9
RTW Investments
New York
– -$17.1M -1,389,705 Closed
RSCM
10
Rock Springs Capital Management
Maryland
– -$13.7M -1,116,578 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$13.1M -1,064,718 Closed
GPP
12
Great Point Partners
Connecticut
– -$12.5M -1,019,153 Closed
BBA
13
Baker Bros. Advisors
New York
– -$9.92M -807,212 Closed
OFM
14
Omega Fund Management
Massachusetts
– -$7.85M -560,985 Closed
SFM
15
Sphera Funds Management
Israel
– -$6.51M -529,640 Closed
State Street
16
State Street
Massachusetts
– -$5.62M -457,674 Closed
VC
17
Vivo Capital
California
– -$5.18M -421,635 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$5.17M -420,310 Closed
SCM
19
Silverarc Capital Management
Massachusetts
– -$4.86M -395,382 Closed
VP
20
venBio Partners
California
– -$4.71M -383,390 Closed
DCM
21
Driehaus Capital Management
Illinois
– -$4.36M -354,729 Closed
SSA
22
Schonfeld Strategic Advisors
New York
– -$3.08M -250,556 Closed
Millennium Management
23
Millennium Management
New York
– -$2.81M -228,773 Closed
Northern Trust
24
Northern Trust
Illinois
– -$2.49M -202,372 Closed
JP Morgan Chase
25
JP Morgan Chase
New York
– -$2.44M -198,946 Closed
1
2 3 4

CINC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q1 2023, worth a combined $0 — down 100% from $461M a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of CINC and 0 opened new positions — a net loss of 102 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sofinnova Investments, exiting entirely with an estimated $74.6M sold.

  • 0 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q1 2023, down from 102 in Q4 2022.
  • Funds reported $0 of CinCor Pharma, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new CinCor Pharma, Inc. Common Stock positions in Q1 2023 and 102 closed out, a net change of -102 holders.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q1 2023 was Sofinnova Investments, an estimated $74.6M sold.

Based on aggregated 13F filings for Q1 2023.